(Reuters) - Analysts on average had expected 51 cents a share, according to Reuters Estimates.
MedImmune said its first-quarter revenue was expected to rise by 11 percent to 12 percent, with net sales growth of 9 percent to 10 percent for Synagis.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment